DDInter624 DDInter393
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Clarithromycin
Efavirenz {u} (Compound) upregulates {v} (Gene) TBX2
TBX2 {u} (Gene) is upregulated by {v} (Compound) Clarithromycin
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Clarithromycin
Efavirenz {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Clarithromycin
Efavirenz {u} (Compound) causes {v} (Side Effect) Connective tissue disorder
Connective tissue disorder {u} (Side Effect) is caused by {v} (Compound) Clarithromycin
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Troleandomycin
Troleandomycin {u} (Compound) resembles {v} (Compound) Clarithromycin
Efavirenz {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Erythromycin
Erythromycin {u} (Compound) resembles {v} (Compound) Clarithromycin
Efavirenz {u} (Compound) upregulates {v} (Gene) TBX2
TBX2 {u} (Gene) regulates {v} (Gene) PHGDH
PHGDH {u} (Gene) is downregulated by {v} (Compound) Clarithromycin
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Fluconazole
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clarithromycin
Efavirenz {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Erythromycin
Erythromycin {u} (Compound) resembles {v} (Compound) Clarithromycin
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Clarithromycin (Compound)
Efavirenz (Compound) upregulates TBX2 (Gene) and TBX2 (Gene) is upregulated by Clarithromycin (Compound)
Efavirenz (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Clarithromycin (Compound)
Efavirenz (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Clarithromycin (Compound)
Efavirenz (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Clarithromycin (Compound)
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Troleandomycin (Compound) and Troleandomycin (Compound) resembles Clarithromycin (Compound)
Efavirenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Erythromycin (Compound) and Erythromycin (Compound) resembles Clarithromycin (Compound)
Efavirenz (Compound) upregulates TBX2 (Gene) and TBX2 (Gene) regulates PHGDH (Gene) and PHGDH (Gene) is downregulated by Clarithromycin (Compound)
Efavirenz (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Fluconazole (Compound) and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Efavirenz (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Erythromycin (Compound) and Erythromycin (Compound) resembles Clarithromycin (Compound)